share_log

AIM ImmunoTech Announces Progress In Ampligen Clinical Trials Targeting Pancreatic Cancer And Long-COVID; Upcoming Milestones Over 18 Months Backed By National Cancer Institute, AstraZeneca, And Merck

AIM ImmunoTech Announces Progress In Ampligen Clinical Trials Targeting Pancreatic Cancer And Long-COVID; Upcoming Milestones Over 18 Months Backed By National Cancer Institute, AstraZeneca, And Merck

AIM ImmunoTech宣佈在針對胰腺癌和長新冠的Ampligen臨牀試驗中取得進展;未來18個月的里程碑將得到國家癌症研究所、阿斯利康和默沙東的支持。
Benzinga ·  01/15 14:14

– Continued execution across Ampligen (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces

– 在滿足關鍵未滿足需求的領域,特別是在高價值的胰腺癌和長新冠領域,持續推進Ampligen(rintatolimod)臨牀開發項目的執行

– Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by the National Cancer Institute, AstraZeneca and Merck

– 在接下來的18個月內預期的里程碑提供了顯著的價值驅動機會,包括一些試驗部分由國家癌症研究所、阿斯利康和默沙東資助

OCALA, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted key clinical, regulatory and corporate milestones achieved over 2024 and outlined its expected upcoming milestones.

佛羅里達州奧卡拉,2025年1月15日(全球新聞資訊)—— AIM ImmunoTech Inc.(紐交所代碼:AIM)(「AIM」或「公司」)今天強調了在2024年實現的關鍵臨牀、監管和公司里程碑,並概述了其預期的即將到來的里程碑。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 356

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。